VA
GILD icon

VestGen Advisors’s Gilead Sciences GILD Stock Holding History

VestGen Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.35M Sell
18,631
-35
-0.2% -$4.61K 0.07% 275
2026
Q1 		$2.52M Sell
18,666
-7,041
-27% -$986K 0.07% 260
2025
Q4 		$3.16M Buy
25,707
+8,957
+53% +$1.09M 0.13% 159
2025
Q3 		$1.86M Buy
16,750
+14,884
+798% +$1.69M 0.06% 259
2025
Q2 		$207K Sell
1,866
-25,709
-93% -$2.74M 0.01% 561
2025
Q1 		$3.09M Buy
+27,575
New +$2.85M 0.14% 149

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

VestGen Advisors's GILD Position: Q2 2026 in Review

VestGen Advisors reduced its Gilead Sciences (GILD) stake by 0.19% in Q2 2026, selling an estimated $4.61K and leaving 18,631 shares worth $2.35M. The position accounts for 0.07% of the portfolio, ranked #275.

VestGen Advisors first reported a position in GILD in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.16M in Q4 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • VestGen Advisors held 18,631 shares of Gilead Sciences worth $2.35M as of Q2 2026.
  • VestGen Advisors sold 35 Gilead Sciences shares in Q2 2026, an estimated $4.61K.
  • Gilead Sciences made up 0.07% of VestGen Advisors's portfolio in Q2 2026, its #275 holding.
  • VestGen Advisors first reported a position in Gilead Sciences in Q1 2025 and has held it in 6 quarters since.
  • VestGen Advisors's Gilead Sciences position peaked at $3.16M in Q4 2025.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on VestGen Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.